Research Projects & Grants

For Profit Organization

• A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD), Role: Investigator, NGM Biopharmaceuticals, Inc., (10/2022 - 10/2023) Status: Completed
• A 64-week, two-arm, randomized, double-masked, multi-center, phase IIIb study assessing the efficacy and safety of Brolucizumab 6 mg compared to Aflibercept 2 mg in a treat-to-control regimen in patients with neovascular age-related macular degeneration (TALON), Role: Investigator, Novartis Pharmaceuticals Corporation, (08/2022 - 08/2023) Status: Completed
• A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema, Role: Investigator, Unity Biotechnology, Inc., (06/2022 - 06/2023) Status: Completed
• A 12-Month, 2-Arm, randomized, double-masked, multicenter Phase III study assessing the efficacy and safety of Brolucizumab every 4 weeks versus Aflibercept every weeks in adult patients with visual impairment due to Diabetic Macular Edema (KINGFISHER), Role: Investigator, Novartis Pharmaceuticals Corporation, (09/2020 - 09/2021) Status: Completed
• A Phase 2b multicenter dose-ranging study evaluating the safety and efficacy of a Long-acting Intravitreal Sunitinib Malate Depot Formulation (GB-102) compared to Intravitreal Aflibercept in subjects with Neovascular (Wet) Age-related Macular Degeneration (ALTISSIMO study), Role: Investigator, Graybug Vision, Inc., (09/2020 - 08/2021) Status: Completed

Internal

• Collection of vitreous and aqueous samples from patient undergoing vitrectomy and intravitreal injections, Role: Investigator, LLU Dept. of Ophthalmology, (03/2020) Status: Approved